ABSTRACT
This study mainly explored the behavioral intention and influencing factors of medical staff toward COVID-19 vaccinations. Medical staff were taken as the research subjects. This study selected 300 research subjects by the intentional sampling method and conducted a questionnaire survey. A total of 260 questionnaires were recovered (a recovery rate of 86%), and the number of valid questionnaires was 212, for an effective questionnaire rate of 81%. SPSS and AMOS were used for statistical analysis. As known from the research results: (1) medical staffs' perception of COVID-19 vaccinations had a positive and significant impact on their behavioral intention for receiving COVID-19 vaccinations; (2) medical staffs' perception of COVID-19 vaccinations had a negative and significant impact on the barriers to receiving COVID-19 vaccinations; (3) medical staffs' motivation of receiving COVID-19 vaccinations had a positive and significant positive effect on their behavioral intention of receiving COVID-19 vaccinations; and (4) medical staffs' motivation of receiving COVID-19 vaccinations had a positive and significant impact on the barrier to receiving COVID-19 vaccinations.
ABSTRACT
BACKGROUND: Respiratory syncytial virus (RSV) is an important viral pathogen responsible for severe infection of the lower respiratory tract in children under the age of 5 years. No vaccines against RSV are currently in clinical use. Vaccine-associated enhanced respiratory disease (ERD) caused by excess Th2 type responses was observed in a clinical trial of formalin-inactivated RSV (FI-RSV) in antigen-naïve infants. Thus, inducing a balanced immune response is a crucial issue in the development of an RSV vaccine. METHODS: In this study, we constructed, expressed, and purified a recombinant RSV vaccine candidate (i.e., HRØ24) containing the two heptad repeat regions and the antigenic sites Ø, II, and IV of the RSV F protein. The RSV vaccine candidate was intranasally administrated to BALB/c and C57BL/6 mice in combination with virus-like particles (VLPs) derived from the core protein of the hepatitis B virus (HBc). Mucosal immunity to HRØ24 was then assessed. RESULTS: Intranasal administration of HBc VLPs in combination with HRØ24 induced serum IgGs against HRØ24 as well as lung HRØ24-specific sIgAs in both C57BL/6 and BALB/c mouse models. The secretion of IFN-γ from splenocyte re-stimulation and an elevated ratio of serum IgG2a to IgG1 indicated that the immune response induced by the HBc VLPs/HRØ24 mixture was Th1-biased. Weight loss of <5% and no to low eosinophil infiltration was observed in histological analysis of the lung following a challenge with the RSV A2 strain. These results suggest that the HBc VLPs/HRØ24 combination conferred substantial partial protection against RSV-induced illness in mice. CONCLUSIONS: Long-term immunity to RSV-induced illness was achieved via intranasal vaccination using a mixture of HBc VLPs and HRØ24 in mouse models.
Subject(s)
Hepatitis B , Respiratory Syncytial Virus Infections , Respiratory Syncytial Virus Vaccines , Respiratory Syncytial Virus, Human , Animals , Antibodies, Viral , Humans , Immunity, Mucosal , Lung , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Respiratory Syncytial Virus Infections/prevention & control , Viral Fusion ProteinsABSTRACT
Recombinant Bacillus subtilis spores expressing a TB antigen, MPT64, were tested for their ability to protect mice against tuberculosis challenge. A chimeric gene consisting of the spore coat gene cotB fused to mpt64 was constructed, and expression of a stable CotB-MPT64 hybrid protein of the spore coat verified. Spores were evaluated as a live vaccine and also formaldehyde inactivated. Mice were given three doses of spores or alternatively used in a prime-boost regimen with BCG. The results showed that inactivated recombinant spores were able to reduce the bacterial burden in the lungs of mice to comparable levels to that of BCG. In the prime-boost regimen, both live and inactivated spores showed a reduction in bacterial load in comparison with BCG. ELISPOT and polyfunctional T-cell analysis were performed to examine cellular responses and showed that antigen-specific secretion of Th1 cytokines was stimulated after immunisation with inactive recombinant spores and BCG. In summary, recombinant spores can elicit Th1 responses, which are important for protection against TB disease.
Subject(s)
Antigens, Bacterial/immunology , Bacillus subtilis/genetics , Drug Carriers , Spores, Bacterial/genetics , Tuberculosis Vaccines/administration & dosage , Tuberculosis Vaccines/immunology , Tuberculosis/prevention & control , Animals , Antigens, Bacterial/genetics , Bacterial Load , Bacterial Proteins/genetics , Cell Surface Display Techniques , Cytokines/metabolism , Disease Models, Animal , Enzyme-Linked Immunospot Assay , Female , Genetic Vectors , Lung/microbiology , Mice , Mice, Inbred C57BL , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/immunology , T-Lymphocytes/immunology , Tuberculosis/immunology , Tuberculosis Vaccines/genetics , Vaccination/methods , Vaccines, Inactivated/administration & dosage , Vaccines, Inactivated/genetics , Vaccines, Inactivated/immunology , Vaccines, Synthetic/administration & dosage , Vaccines, Synthetic/genetics , Vaccines, Synthetic/immunologyABSTRACT
Needle-free, mucosal immunization is a highly desirable strategy for vaccination against many pathogens, especially those entering through the respiratory mucosa, such as Mycobacterium tuberculosis. Unfortunately, mucosal vaccination against tuberculosis (TB) is impeded by a lack of suitable adjuvants and/or delivery platforms that could induce a protective immune response in humans. Here, we report on a novel biotechnological approach for mucosal vaccination against TB that overcomes some of the current limitations. This is achieved by coating protective TB antigens onto the surface of inert bacterial spores, which are then delivered to the respiratory tract. Our data showed that mice immunized nasally with coated spores developed humoral and cellular immune responses and multifunctional T cells and, most importantly, presented significantly reduced bacterial loads in their lungs and spleens following pathogenic challenge. We conclude that this new vaccine delivery platform merits further development as a mucosal vaccine for TB and possibly also other respiratory pathogens.
Subject(s)
Antigens, Bacterial/immunology , Mycobacterium tuberculosis/immunology , Tuberculosis Vaccines/immunology , Tuberculosis/prevention & control , Vaccination/methods , Administration, Intranasal , Administration, Mucosal , Animals , Antibodies, Bacterial/immunology , Antigens, Bacterial/administration & dosage , Bacterial Load , Cell Surface Display Techniques , Disease Models, Animal , Drug Carriers/administration & dosage , Female , Lung/microbiology , Male , Mice , Mice, Inbred C57BL , Spleen/microbiology , Spores, Bacterial/immunology , T-Lymphocytes/immunology , Tuberculosis/immunology , Tuberculosis Vaccines/administration & dosageABSTRACT
Heat killed spores of the Gram-positive bacterium Bacillus subtilis have been evaluated as a vaccine delivery system with mucosal adjuvant properties for influenza. Killed spores were able to bind H5N1 virions (NIBRG-14; clade 1) and, when intra-nasally administered to mice, resulting immune responses, both humoral and cell mediated, were enhanced compared to immunization with the virion alone. Levels of both systemic IgG and mucosal sIgA specific to the virion were elevated. Levels of IgG2a (a Th(1) antibody type) were strongly enhanced when the virion was co-administered with killed spores. Cytokine induction in stimulated splenocytes was also apparent indicating balanced T(h)1 and T(h)2 responses. Evidence of cross-neutralization of clade 2.2 viruses was shown. In a challenge experiment mice dosed two times with spores adsorbed with just 20 ng HA (hemagglutinin) of inactivated NIBRG-14 were fully protected against challenge with 20 LD(50) of H5N2 virus. Interestingly, partial protection (60%) was observed in animals dosed only with killed spores. Mice dosed only with killed spores were shown to be fully protected against H5N2 (5 LD(50)) infection indicating that innate immunity and its stimulation by spores may play an important role in protection. Supporting this killed spores were (i) shown to stimulate TLR-mediated expression of NF-κB, and (ii) able to recruit NK cells into lungs and induce maturation of DCs. This work demonstrates the potential and underlying mechanism for the use of bacterial spores as an adjuvant for H5N1 vaccination.
Subject(s)
Adjuvants, Immunologic/administration & dosage , Bacillus subtilis/immunology , Influenza A Virus, H5N1 Subtype/immunology , Influenza Vaccines/immunology , Spores, Bacterial/immunology , Administration, Intranasal , Animals , Antibodies, Neutralizing/blood , Antibodies, Viral/analysis , Antibodies, Viral/blood , Cross Reactions , Cytokines/biosynthesis , Disease Models, Animal , Female , Immunity, Mucosal , Immunoglobulin A/analysis , Immunoglobulin G/blood , Influenza A Virus, H5N2 Subtype/immunology , Influenza A Virus, H5N2 Subtype/pathogenicity , Influenza Vaccines/administration & dosage , Leukocytes, Mononuclear/immunology , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Orthomyxoviridae Infections/prevention & control , Spleen/immunology , Survival AnalysisABSTRACT
Clostridium difficile is a leading cause of nosocomial infection in the developed world. Two toxins, A and B, produced by most strains of C. difficile are implicated as virulence factors, yet only recently has the requirement of these for infection been investigated by genetic manipulation. Current vaccine strategies are focused mostly on parenteral delivery of toxoids. In this work, we have used bacterial spores (Bacillus subtilis) as a delivery vehicle to evaluate the carboxy-terminal repeat domains of toxins A and B as protective antigens. Our findings are important and show that oral immunization of the repeat domain of toxin A is sufficient to confer protection in a hamster model of infection designed to closely mimic the human course of infection. Importantly, neutralizing antibodies to the toxin A repeat domain were shown to be cross-reactive with the analogous domain of toxin B and, being of high avidity, provided protection against challenge with a C. difficile strain producing toxins A and B (A(+)B(+)). Thus, although many strains produce both toxins, antibodies to only toxin A can mediate protection. Animals vaccinated with recombinant spores were fully able to survive reinfection, a property that is particularly important for a disease with which patients are prone to relapse. We show that mucosal immunization, not parenteral delivery, is required to generate secretory IgA and that production of these neutralizing polymeric antibodies correlates with protection. This work demonstrates that an effective vaccine against C. difficile can be designed around two attributes, mucosal delivery and the repeat domain of toxin A.
Subject(s)
Bacillus subtilis/immunology , Bacterial Proteins/immunology , Bacterial Toxins/immunology , Bacterial Vaccines/immunology , Clostridioides difficile/immunology , Enterocolitis, Pseudomembranous/prevention & control , Enterotoxins/immunology , Animals , Antibodies, Bacterial/immunology , Cricetinae , Cross Protection/immunology , Enterocolitis, Pseudomembranous/immunology , Enterocolitis, Pseudomembranous/microbiology , Enzyme-Linked Immunosorbent Assay , Female , Mesocricetus , Mice , Mice, Inbred BALB C , Neutralization Tests , Spores, Bacterial/immunology , Vaccines, Synthetic/immunologyABSTRACT
Attenuated Salmonella enterica offers a vaccine delivery route that has the benefits of enhanced immunogenicity and oral delivery. The majority of immunization studies have been conducted to deliver recombinant proteins, expressed from a gene that is either chromosomally integrated or carried on a low- or medium-copy number plasmid. There are, however, an increasing number of reports demonstrating the delivery of DNA vaccines, but the high-copy number plasmids that are preferentially used for this application are unstable in Salmonella. Here, we use the Operator-Repressor Titration (ORT) plasmid maintenance system in Salmonella enterica serovar Typhimurium to deliver a high-copy number plasmid expressing the Mycobacterium tuberculosis gene mpt64 to mice. MPT64 expression was detected in phagocytes using immunofluorescence microscopy following Salmonella-mediated delivery of the DNA vaccine. The indicative CD8+ responses measured by antigen-specific IFN-γ were higher from the live bacterial vector than from injected plasmid DNA, and a reduction in the pulmonary bacterial load was seen following an aerogenic challenge. This illustrates the potential of live attenuated Salmonella as oral tuberculosis vaccine vectors.
Subject(s)
Antigens, Bacterial/immunology , Tuberculosis Vaccines/immunology , Tuberculosis/prevention & control , Vaccines, DNA/immunology , Administration, Oral , Animals , Bacterial Load , CD8-Positive T-Lymphocytes/immunology , Cell Line , Epitopes, T-Lymphocyte/immunology , Female , Genetic Vectors , Immunity, Cellular , Interferon-gamma/immunology , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Phagocytes/immunology , Plasmids/immunology , Salmonella enterica/immunology , Tuberculosis/immunology , Tuberculosis Vaccines/administration & dosage , Vaccines, Attenuated/administration & dosage , Vaccines, Attenuated/immunology , Vaccines, DNA/administration & dosageABSTRACT
The development of new-generation vaccines has followed a number of strategic avenues including the use of live recombinant bacteria. Of these, the use of genetically engineered bacterial spores has been shown to offer promise as both a mucosal as well as a heat-stable vaccine delivery system. Spores of the genus Bacillus are currently in widespread use as probiotics enabling a case to be made for their safety. In this work we have discovered that the negatively charged and hydrophobic surface layer of spores provides a suitable platform for adsorption of protein antigens. Binding can be promoted under conditions of low pH and requires a potent combination of electrostatic and hydrophobic interactions between spore and immunogen. Using appropriately adsorbed spores we have shown that mice immunised mucosally can be protected against challenge with tetanus toxin, Clostridium perfringens alpha toxin and could survive challenge with anthrax toxin. In some cases protection is actually greater than using a recombinant vaccine. Remarkably, killed or inactivated spores appear equally effective as live spores. The spore appears to present a bound antigen in its native conformation promoting a cellular (T(h)1-biased) response coupled with a strong antibody response. Spores then, should be considered as mucosal adjuvants, most similar to particulate adjuvants, by enhancing responses against soluble antigens. The broad spectrum of immune responses elicited coupled with the attendant benefits of safety suggest that spore adsorption could be appropriate for improving the immunogenicity of some vaccines as well as the delivery of biotherapeutic molecules.
Subject(s)
Antigens, Bacterial/chemistry , Antigens, Bacterial/immunology , Bacillus subtilis/chemistry , Bacillus subtilis/immunology , Spores, Bacterial/chemistry , Spores, Bacterial/immunology , Adsorption , Animals , Anthrax/prevention & control , Antibodies, Bacterial/blood , Clostridium Infections/prevention & control , Female , Mice , Mice, Inbred BALB C , Protein Binding , T-Lymphocytes/immunology , Tetanus/prevention & controlABSTRACT
Endospores of the Gram-positive bacterium, Bacillus subtilis, have been used successfully for delivery of antigens where the immunogen is expressed on the spore surface. In this work the spore has been engineered to deliver antigens to the cytoplasm of macrophages by expressing listeriolysin O (LLO) or a derivative, LLO(L461T), that is stable at neutral pH, from the B. subtilis vegetative cell. Following phagocytosis spores were shown to germinate in the phagosome enabling secretion of LLO/LLO(L461T) and entry of the bacterium into the cytosol. We have shown that in the cytosol B. subtilis proliferates before eventually being destroyed. Immunisation of mice with spores that co-expressed LLO with Protective Antigen (PA) of Bacillus anthracis generated an increase in IgG2a against PA, toxin-neutralising activity coupled with specific IFN-gamma and IL-12 (and reduced IL-4) responses of splenocytes, both indicative of an enhanced Th1 response. Enhanced Th1 responses via LLO co-expression of antigen by B. subtilis spores may be a useful strategy to improve vaccine performance.
Subject(s)
Bacillus subtilis/immunology , Bacterial Toxins/genetics , Bacterial Toxins/immunology , Cytoplasm , Heat-Shock Proteins/genetics , Heat-Shock Proteins/immunology , Hemolysin Proteins/genetics , Hemolysin Proteins/immunology , Th1 Cells/immunology , Animals , Antibody Formation/immunology , Bacillus subtilis/genetics , Bacterial Toxins/biosynthesis , Cell Survival , Female , Flow Cytometry , Heat-Shock Proteins/biosynthesis , Hemolysin Proteins/biosynthesis , Hemolysis/drug effects , Hemolysis/genetics , Immunoglobulin A/biosynthesis , Immunoglobulin A/genetics , Interferon-gamma/biosynthesis , Interferon-gamma/genetics , Interleukin-12/biosynthesis , Interleukin-12/genetics , Mice , Mice, Inbred BALB C , Microscopy, Confocal , Microscopy, Electron, Transmission , Microscopy, Fluorescence , Neutralization Tests , Phagocytes/immunology , Recombinant Proteins/biosynthesis , Recombinant Proteins/genetics , Spleen/cytology , Spleen/immunology , Spores, Bacterial/immunologyABSTRACT
Bacillus species, typically Bacillus subtilis, are being used as probiotics and mounting evidence indicates that Bacillus species are important for development of a robust gut-associated lymphoid system (GALT). We used a number of gut isolates of Bacillus incorporating three species, B. subtilis, Bacillus licheniformis and Bacillus flexus to evaluate the nature of interaction between spores and the GALT. In mice orally administered with spores, evidence of cell proliferation was determined in the germinal centers of Peyer's patches. Stimulation of antigen-presenting cells and T lymphocytes was also markedly enhanced. Cytokines were shown to be induced in spleens and mesenteric lymph nodes of mice including the proinflammatory cytokines, tumour necrosis factor-alpha and IL-6. We also demonstrated that vegetative cells of B. subtilis can stimulate expression of the toll-like receptor (TLR) genes for TLR2 and TLR4. However, we were able to show that spores could not stimulate either and must, by default, interact with another TLR and by this mechanism help activate innate immunity.